RALP vs. ORP: data from a randomized Phase III clinical trial

A newly published paper in The Lancet has provided us with data from a randomized, Phase III, clinical trial of open radical retropubic prostatecomy (ORP) vs. robot-assisted laparoscopic prostatectomy (RALP) in the surgical treatment of localized prostate cancer. … READ MORE …

Defining value in the management of prostate cancer

Many years ago, among his other famous quotations on the subject of prostate cancer, Willet Whitmore, considered by many to be the “father” of urologic oncology, stated the following: … READ MORE …

Maybe PD-1 inhibitors have a role in advanced prostate cancer after all!

New immunotherapeutic drugs known as PD-1 inhibitors (drugs like nivolumab/Optivo and pembrolizumab/Keytruda) have shown some remarkable effects in the treatment of advanced forms of cancer like melanoma and some forms of lung cancer. … READ MORE …

Results we already knew about for cabozantinib in mCRPC

Back in September 2014, Exelixis had announced (and we had reported) the failure of the COMET-1 trial to show a meaningful survival benefit for treatment with cabozantinib in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Hypofractionated radiation therapy for localized prostate cancer: an update

Within the past year, we have reviewed several major randomized clinical trials comparing hypofractionated radiation therapy to conventionally fractionated radiation therapy for primary treatment of localized prostate cancer. … READ MORE …

Intermittent vs. continuous chemotherapy for men with CRPC

One of the small number of major prostate cancer presentations at the ASCO meeting this year comes from the so-called PRINCE trial of intermittent chemotherapy in men with castration-resistant prostate cancer (CRPC). … READ MORE …

Improvements in the quality of prostate cancer care (in Australia)

One of the most critical issues for many in the prostate cancer community is whether patients actually receive treatment according to standard guidelines. While getting treatment according to standard guidelines may not imply that a patient is getting the very best possible care, we know that getting treatment according to standard guidelines does at least mean that physicians are seeking to meet or surpass the quality of care that is recommended.

A new paper by Sampurno et al. in the Medical Journal of Australia has provided us with data from the Prostate Cancer Outcomes Registry–Victoria (PCOR-Vic), a state-wide prostate cancer outcomes registry in Victoria (one of Australia’s most highly populated states).

The authors collected and analyzed data on 4,708 men diagnosed with prostate cancer over a 5-year period (from 1 January 2009 and 31 December 2013). The goal was to assess how well prostate cancer care was being delivered when measured against three predefined quality indicators:

  • Alignment with the modified Prostate Cancer Research International Active Surveillance (PRIAS) protocol guideline (QI-1)
  • Timeliness of prostate cancer care for men with high-risk and locally advanced disease (QI-2)
  • The presence of positive surgical margins (PSMs) among men treated surgically for organ-confined, pT2 disease (QI-3)

The entire text of this paper is available on line for interested readers, so we will focus on the “top-line” results of the study, as follows:

  • Over the 5 years of the study there was
    • A downward trend in the percentage of men with low-risk disease who underwent active treatment (from 45 to 34 percent; P = 0.024)
    • An upward trend in the percentage of men with high-risk and locally advanced disease who received active treatment within 12 months of diagnosis (from 88 to 93 percent; P = 0.181)
    • A decline in PSM rate among men with pT2 disease after radical prostatectomy (from 21 to 12 percent; P = 0.036)

The authors note that a limitation of the study is that the improvement in the quality indicators was detected using PCOR-Vic as a single population, but that there could still be institutional variations in quality improvement.

With that reservation, the authors conclude that, over the period 2009 t0 2013

the performance of the Victorian health system improved according to the three processes of care indicators reported by the PCOR-Vic.

The “New” Prostate Cancer InfoLink sees this as an important study because it offers (a) validation of the processes being used in Australia to set and then achieve certain standards of care and (b) a significant set of improvements over 5 years toward achieving such standards of care.

By comparison, in much of America, there are no predefined goal being set by anyone as to levels of acceptable outcomes, nor are there clear educational processes in most states designed to ensure that physicians are seeking to meet or exceed such outcomes.


Get every new post delivered to your Inbox.

Join 1,449 other followers